AbbVie Inc. · News & developments
AbbVie Sets Stage for Pivotal Phase 3 Etentamig Presentation at IMS 2026
AbbVie announced that complete results from its Phase 3 CERVINO trial will be presented in a plenary session at the 23rd International Myeloma Society Annual Meeting held September 23–26, 2026. A plenary presentation will feature full results from the Phase 3 CERVINO study evaluating investigational drug etentamig, a second-generation BCMA x CD3 bispecific T-cell engager. Topline results showed etentamig met its dual primary endpoints of objective response rate and progression-free survival versus standard available therapies in triple-class exposed relapsed/refractory multiple myeloma. AbbVie will also present data on trispecific candidate ABBV-2001 and BCL-2 inhibitor surzetoclax.
Why this matters
Multiple myeloma is an increasingly crowded commercial field, but succeeding in triple-class exposed patients clears the regulatory hurdle required for commercial approval. Meeting primary survival and response endpoints against standard active care validates AbbVie's pipeline beyond established hematology blockbusters. If detailed plenary disclosures show manageable safety without severe competitive disadvantages in tolerability, AbbVie secures a credible late-stage oncology engine capable of driving long-term enterprise value.